JAGUAR HEALTH, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
JAGUAR HEALTH, INC. (JAGX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$48.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-04-07
- JAGUAR HEALTH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$48.80M.
- JAGUAR HEALTH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$34.30M.
- JAGUAR HEALTH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$35.60M.
- JAGUAR HEALTH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$42.10M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$48.80M 10-K · filed 2026-04-07 |
| 2024-12-31 | -$34.30M 10-K · filed 2026-04-07 |
| 2023-12-31 | -$35.60M 10-K · filed 2025-03-31 |
| 2022-12-31 | -$42.10M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |